See more : Bâloise Holding AG (BLHEF) Income Statement Analysis – Financial Results
Complete financial analysis of Shanghai HeartCare Medical Technology Corporation Limited (6609.HK) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Shanghai HeartCare Medical Technology Corporation Limited, a leading company in the Medical – Devices industry within the Healthcare sector.
- PGE Polska Grupa Energetyczna S.A. (PGPKY) Income Statement Analysis – Financial Results
- Encres Dubuit (ALDUB.PA) Income Statement Analysis – Financial Results
- Shinpo Co., Ltd. (5903.T) Income Statement Analysis – Financial Results
- Okapi Resources Limited (OKR.AX) Income Statement Analysis – Financial Results
- Exide Industries Limited (EXIDEIND.NS) Income Statement Analysis – Financial Results
Shanghai HeartCare Medical Technology Corporation Limited (6609.HK)
About Shanghai HeartCare Medical Technology Corporation Limited
Shanghai HeartCare Medical Technology Corporation Limited engages in the research, development, manufacture, and sale of neuro-interventional medical devices worldwide. The company offers ischemic stroke thrombectomy, intracranial stenosis treatment, ischemic stroke prevention, hemorrhagic stroke treatment, and vascular access devices. Its products are used for the treatment and prevention of ischemic stroke, including acute ischemic stroke and intracranial stenosis, as well as for the treatment of hemorrhagic stroke. The company was formerly known as Shanghai Care Medical Technology Corporation Limited. Shanghai HeartCare Medical Technology Corporation Limited was incorporated in 2016 and is headquartered in Shanghai, the People's Republic of China.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|
| Revenue | 232.34M | 183.03M | 90.09M | 14.56M | 0.00 |
| Cost of Revenue | 68.59M | 58.70M | 35.14M | 7.48M | 0.00 |
| Gross Profit | 163.76M | 124.33M | 54.95M | 7.09M | 0.00 |
| Gross Profit Ratio | 70.48% | 67.93% | 61.00% | 48.67% | 0.00% |
| Research & Development | 123.83M | 153.69M | 76.31M | 51.13M | 51.11M |
| General & Administrative | 74.64M | 71.47M | 115.89M | 27.36M | 7.38M |
| Selling & Marketing | 79.25M | 96.53M | 51.13M | 14.28M | 1.04M |
| SG&A | 153.88M | 167.99M | 167.02M | 41.63M | 8.42M |
| Other Expenses | -113.95M | -11.88M | -8.99M | 120.66M | 16.25M |
| Operating Expenses | 163.76M | 309.81M | 234.34M | 213.43M | 75.78M |
| Cost & Expenses | 344.30M | 368.51M | 269.48M | 220.90M | 75.78M |
| Interest Income | 11.20M | 15.14M | 5.50M | 174.00K | 67.00K |
| Interest Expense | 2.16M | 2.15M | 2.36M | 1.60M | 62.00K |
| Depreciation & Amortization | 32.26M | 31.79M | 12.20M | 8.39M | 1.48M |
| EBITDA | -68.50M | -167.31M | -183.34M | -206.19M | -73.37M |
| EBITDA Ratio | -29.48% | -91.12% | -204.36% | -1,410.40% | 0.00% |
| Operating Income | -126.87M | -198.57M | -196.31M | -213.77M | -75.71M |
| Operating Income Ratio | -54.60% | -108.49% | -217.91% | -1,467.98% | 0.00% |
| Total Other Income/Expenses | 23.95M | -2.68M | -1.59M | -2.42M | 3.05M |
| Income Before Tax | -102.92M | -201.25M | -197.91M | -216.18M | -75.50M |
| Income Before Tax Ratio | -44.30% | -109.95% | -219.68% | -1,484.57% | 0.00% |
| Income Tax Expense | -8.91M | -865.00K | -2.09M | -103.00K | -210.00K |
| Net Income | -94.01M | -200.38M | -195.82M | -216.08M | -75.29M |
| Net Income Ratio | -40.46% | -109.48% | -217.36% | -1,483.86% | 0.00% |
| EPS | -2.47 | -5.24 | -5.86 | -5.56 | -1.94 |
| EPS Diluted | -2.47 | -5.24 | -5.86 | -5.56 | -1.94 |
| Weighted Avg Shares Out | 38.08M | 38.27M | 33.40M | 38.83M | 38.83M |
| Weighted Avg Shares Out (Dil) | 38.08M | 38.27M | 33.40M | 38.83M | 38.83M |
Source: https://incomestatements.info
Category: Stock Reports